From MIT to NYSE: How One Company Went from University to Acquisition – November 12

 

LucchinoThis special event features David L. Lucchino, Current VDC Entrepreneur in Residence and Christopher Loose, Former Co-founder and VP of Semprus Biosciences.

David L. Lucchino co-founded and served as CEO of Semprus BioSciences until its acquisition by Teleflex (NYSE: TFX) in 2012 for $80M. David served as a Vice President to execute a post-merger integration plan that ended December 2013. Teleflex has over 13,000 employees worldwide. With his business plan for Semprus, David led his MIT colleagues to achieve first place in entrepreneurial competitions at MIT, Harvard and Oxford Universities. Under his stewardship, David grew Semprus from two to 50 employees, secured $28.5M in venture capital financing and $8.4M in federal funding, and received FDA approval for its first product.  Prior to co-founding Semprus, David was a senior executive at Polaris Venture Partners, a $3B venture capital fund based in Boston. He co-founded and served as Managing Director of LaunchCyte, an investment firm that specializes in developing biomedical intellectual property. He is board member for Lipella Pharmaceuticals Inc., a privately held development-stage biotechnology company. 

 Dr. Christopher Loose serves as Executive Director of Yale University’s Center for Biomedical and Interventional Technology (CBIT).  He also holds an appointment as Assistant Professor Adjunct of Urology in the Yale School of Medicine. Additionally, Dr. Loose is an Accelerator Executive at the Center for Integration of Medicine and Innovative Technology (CIMIT).  Dr. Loose received the prestigious Hertz Foundation Fellowship and was selected by MIT’s Technology Review as a member of the “TR35,” naming the world’s top 35 innovators under the age of 35. He was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation in 2011 and was also named to Boston Business Journal’s 40 emerging business leaders under 40.  While earning his PhD. in Chemical Engineering at MIT, Dr. Loose co-authored the Semprus Biosciences business plan which won entrepreneurial competitions at MIT, Harvard University and Oxford University.  Prior to his graduate work, Dr. Loose was a chemical engineer at Merck Research Labs after graduating summa cum laude with a B.S.E in Chemical Engineering from Princeton University.

How to RSVP:

UMass Boston Students:  We are requiring students to register for a short online course by and this will be your registration for the event.  The following link will take you to the homepage of the course and to register, click on the orange button that says “Click here to start this free course!”: https://vdcjobs.coursesites.com/ Please note that you are NOT required to complete the course to attend this event, only that you register.

UMass Boston Faculty, Staff and Guests: Follow the provided link, https://www.eventbrite.com/e/from-mit-to-nyse-how-one-company-went-from-university-to-acquisition-tickets-14194202241